New arthritis drug candidate SHR-3045 tested in healthy volunteers

NCT ID NCT07200596

Completed Disease control Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 study tested a single injection of SHR-3045 in 16 healthy adults to see if it is safe and how the body processes it. The drug is being developed as a potential treatment for rheumatoid arthritis, an autoimmune disease that causes joint pain and swelling. Because this is a very early trial, it does not yet test whether the drug actually helps arthritis patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-3045
What this could lead to: If this early study shows SHR-3045 is safe, it could lead to larger trials testing whether it can help control rheumatoid arthritis.
What could go wrong: This is a very early Phase 1 trial with only 16 healthy people, not patients. It only checks safety and how the drug moves through the body, not whether it works for arthritis. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Locations

The Frist Affiliated Hospital of USTC (Anhui Provincial Hospital)

Hefei, Anhui, 230001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.